Compare PCRX & HKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | HKD |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 499.7M |
| IPO Year | 2010 | 2021 |
| Metric | PCRX | HKD |
|---|---|---|
| Price | $22.01 | $1.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $37.60 | N/A |
| AVG Volume (30 Days) | ★ 773.2K | 590.1K |
| Earning Date | 05-07-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $9.77 | N/A |
| Revenue Next Year | $9.71 | N/A |
| P/E Ratio | $141.53 | ★ $14.10 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $1.26 |
| 52 Week High | $27.99 | $5.47 |
| Indicator | PCRX | HKD |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 43.40 |
| Support Level | $20.09 | $1.34 |
| Resistance Level | $23.82 | $1.69 |
| Average True Range (ATR) | 1.06 | 0.10 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 32.59 | 35.94 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment; hotel operations, hospitality and VIP services segment; media and entertainment services segment; and Strategic investments. The company generates maximum revenue from Digital solutions services segment, which provides its institutional and corporate clients with exclusive, paid access to enhance their investor communication, investor relations and corporate communication to potentially maximize their valuation, as well as providing digital solution services. Geographically, the company generates revenue from China, Hong Kong, Europe, Americas and Southeast Asia.